Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.58 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 3/20 | 0.51 |
| ▸ | TDO2 | P48775 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.49 |
| ▸ | HTR3B | O95264 | 1/20 | 0.49 |
| ▸ | HTR3A | P46098 | 1/20 | 0.49 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.49 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9967760 | 0.89 | PNMT (0.55) | PNMTAOC3TAAR1TSHRRECQL | |
| SCHEMBL25786628 | 0.85 | PNMT (0.51) | PNMTAOC3TAAR1TSHRRECQL | |
| SCHEMBL9579004 | 0.85 | OPRM1 (0.50) | PNMTAOC3TAAR1KMT2AOPRM1 | |
| SCHEMBL28647619 | 0.85 | PNMT (0.55) | PNMTAOC3TAAR1TSHRRECQL | |
| SCHEMBL5149468 | 0.85 | TSHR (0.58) | PNMTAOC3TAAR1TSHRRECQL | |
| SCHEMBL265738 | 0.85 | PNMT (0.70) | PNMTAOC3TAAR1TSHRRECQL | |
| SCHEMBL8293508 | 0.83 | PNMT (0.53) | PNMTAOC3TAAR1TSHRRECQL | |
| SCHEMBL13995331 | 0.83 | TAAR1 (0.60) | PNMTAOC3TAAR1TSHRRECQL | |
| SCHEMBL28658363 | 0.82 | PNMT (0.51) | PNMTAOC3TAAR1TSHRRECQL | |
| SCHEMBL12050856 | 0.80 | TAAR1 (0.74) | PNMTAOC3TAAR1IDO1HTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1535151-A | Novel anti-infectives | ʷ��˿�������ȳ�ķ����˾ | 2004-10-06 | — | — | CN | claimed |
| CN-117720415-A | Application of Salen-Ti complex catalyst in preparation of quaternary carbon-containing compound by using halohydrocarbon | 山东大学 | 2024-03-19 | — | — | CN | disclosed |
| US-11701345-B2 | Car activator agents for cyclophosphamide-based treatments of cancer | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701345-B2 | Car activator agents for cyclophosphamide-based treatments of cancer | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-07-18 | — | — | US | disclosed |
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2022-05-19 | — | — | US | disclosed |
| US-20210186970-A1 | SELECTIVE CALCIUM CHANNEL ANTAGONISTS | NORTHWESTERN UNIVERSITY | 2021-06-24 | — | — | US | disclosed |
| EP-3534709-B1 | SUBSTITUTED SULFONYLAMIDE FOR COMBATING ANIMAL PESTS | BAYER AG (DE) | 2021-06-16 | — | — | EP | disclosed |
| US-20200352915-A1 | CAR ACTIVATOR AGENTS FOR CYCLOPHOSPHAMIDE-BASED TREATMENTS OF CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-11-12 | — | — | US | disclosed |
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | AFASCI, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| WO-2020027304-A1 | NOVEL CAROTENOID-RELATED DERIVATIVES, AND SALTS, ESTERS, OR AMIDES THEREOF | アスタファーマシューティカルズ株式会社 | 2020-02-06 | — | — | WO | disclosed |
| US-7449447-B2 | Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2008-11-11 | — | — | US | disclosed |
| US-7378413-B2 | 2-amino-3-(alkyl)-pyrimidone derivatives | SANOFI AVENTIS (FR) | 2008-05-27 | — | — | US | disclosed |
| US-7348326-B2 | Heteroaryl fused aminoalkyl imidazole derivatives: selective modulators of GABAa receptors | NEUROGEN CORPORATION (US) | 2008-03-25 | — | — | US | disclosed |
| US-7196095-B2 | (Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds | MERCK & CO., INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-20060160842-A1 | Heteroaryl fused aminoalkyl imidazole derivates: selective modulators of GABAA receptors | NEUROGEN CORPORATION (US) | 2006-07-20 | — | — | US | disclosed |
| US-6972293-B2 | Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors | NEUROGEN CORPORATION (US) | 2005-12-06 | — | — | US | disclosed |
| WO-2005021584-A2 | NOVEL PEPTIDOMIMETIC NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2005-03-10 | — | — | WO | disclosed |
| CN-1535151-A | Novel anti-infectives | ʷ��˿�������ȳ�ķ����˾ | 2004-10-06 | — | — | CN | disclosed |
| US-6627624-B1 | Agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain receptors, and are therefore useful in the diagnosis and treatment of anxiety, Down Syndrome, | NEUROGEN CORPORATION | 2003-09-30 | — | — | US | disclosed |
| US-6380210-B1 | USEFUL IN DIAGNOSIS AND TREATMENT OF ANXIETY, DOWN SYNDROME, SLEEP, COGNITIVE AND SEIZURE DISORDERS, DEPRESSION, OVERDOSE WITH BENZODIAZEPINE DRUGS, AND ENHANCEMENT OF MEMORY AND ALERTNESS | NEUROGEN CORPORATION | 2002-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | CACNA1I, CACNA1G, CACNA1H | PNMT 783/4885AOC3 3775/4885TAAR1 1302/4885 |
| US-11701345-B2 | Car activator agents for cyclophosphamide-based treatments of cancer | CYP2A6, CYP2B6, CYP4A11 | PNMT 3085/4885AOC3 1553/4885TAAR1 1473/4885 |
| US-20060160842-A1 | Heteroaryl fused aminoalkyl imidazole derivates: selective modulators of GABAA receptors | GABRB1, GABRA1, GABRB3 | PNMT 2548/4885AOC3 1519/4885TAAR1 89/4885 |
| US-20200352915-A1 | CAR ACTIVATOR AGENTS FOR CYCLOPHOSPHAMIDE-BASED TREATMENTS OF CANCER | CYP2A6, CYP2B6, CYP4A11 | PNMT 3085/4885AOC3 1553/4885TAAR1 1473/4885 |
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | PNMT 4799/4885AOC3 4061/4885TAAR1 4274/4885 |
| US-20210186970-A1 | SELECTIVE CALCIUM CHANNEL ANTAGONISTS | CACNA1C, CACNA1B, CACNA1G | PNMT 2226/4885AOC3 975/4885TAAR1 1963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.